Anthera Raises $33M After Stock Bump on Lupus Data
By Staff Reports
Monday, July 23, 2012
After getting hammered a month ago on news of a missed primary endpoint in the Phase IIb PEARL-SC study of lupus drug blisibimod, shares of Anthera Pharmaceuticals Inc. rebounded last week when the Hayward, Calif.-based firm released promising data from a subset of patients in the study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.